EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases

Maria A Theodoropoulou iD, Christiana Mantzourani iD, George Kokotos iD

Biomolecules · 2024

DOI: 10.3390/biom14121605 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, 2024. Verfasst von Maria A Theodoropoulou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece. Hauptthemen laut MEDLINE: Histone Deacetylase Inhibitors, Fibrosis, Inflammation, Histone Deacetylases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: General Secretariat of Research and Innovation, General Secretariat of Research, Innovation (GSRI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Histone deacetylases (HDACs) are enzymes that play an essential role in the onset and progression of cancer. As a consequence, a variety of HDAC inhibitors (HDACis) have been developed as potent anticancer agents, several of which have been approved by the FDA for cancer treatment. However, recent accumulated research results have suggested that HDACs are also involved in several other pathophysiological conditions, such as fibrotic, inflammatory, neurodegenerative, and autoimmune diseases. Very recently, the HDAC inhibitor givinostat has been approved by the FDA for an indication beyond cancer: the treatment of Duchenne muscular dystrophy. In recent years, more and more HDACis have been developed as tools to understand the role that HDACs play in various disorders and as a novel therapeutic approach to fight various diseases other than cancer. In the present perspective article, we discuss the development and study of HDACis as anti-fibrotic and anti-inflammatory agents, covering the period from 2020–2024. We envision that the discovery of selective inhibitors targeting specific HDAC isozymes will allow the elucidation of the role of HDACs in various pathological processes and will lead to the development of promising treatments for such diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Histone Deacetylase InhibitorsFibrosisInflammationHistone DeacetylasesHumansAnimalsAnti-Inflammatory Agents

Stichwörter der Autor:innen

HDAC inhibitorsHDACsfibrosisidiopathic pulmonary fibrosisinflammation

Substanzen

Histone Deacetylase InhibitorsHistone DeacetylasesAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece.
  • Center of Excellence for Drug Design and Discovery, National and Kapodistrian University of Athens, 15771 Athens, Greece.

ORCID-Profile: Maria A Theodoropoulou, Christiana Mantzourani, George Kokotos

Förderung

  • General Secretariat of Research and Innovation
  • General Secretariat of Research
  • Innovation (GSRI)
  • European Union (Next Generation EU)

Zitieren

APA

Theodoropoulou, M. A., Mantzourani, C., & Kokotos, G. (2024). Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases. Biomolecules. https://doi.org/10.3390/biom14121605

Vancouver

Theodoropoulou MA, Mantzourani C, Kokotos G. Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases. Biomolecules. 2024. doi:10.3390/biom14121605

BibTeX
@article{Theodoropoulou2024,
  author = {Theodoropoulou, Maria A and Mantzourani, Christiana and Kokotos, George},
  title = {Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory Diseases},
  journal = {Biomolecules},
  year = {2024},
  doi = {10.3390/biom14121605}
}
Kostenlos starten →